Investors are dissapointed growth won't continue at the pace of the June qtr. However it will still be low-mid single digit growth, instead of 6% in the June qtr. If we look at the Sept 2012 qtr, we can see they made $10M+ more in revenues than this last June qtr. If we simply see the low-mid single digit growth the company is talking about, they should have a much better qtr in Sept than they had in June. Also the CEO stated the enterprise value of the company at $209M. That would come to over $5/share.
Could there be bad news coming($8.60 to $7.05 in recent weeks)- sure hope not. Super cheap(around a 4 PE going forward), buying back shares, raised their dividend, and no hurricaines, yet the stock doesn't want to rally ?
of consessions by the new Egyptian government that will increase acreage for TGA by 160% ? I'm stumped, as this news basically counters restriction concerns from the previous government, and creates a huge potential for greater production for TGA for years to come !
Thing, the stock has tested the $10.30 area today over and over, and failed. Looks like it wants to retest the $9.15 low from yesterday, and go the mid $8s before rallying.
glhsken, I meant a 50% pullback of the $6 profit from $5.50 to $11.50. Stocks retrace 50%-60% of short term gains all the time before rallying again- even when nothing is wrong.
Unless news has leaked, we are simply seeing a technical pullback of the $3 gain from $8.80 to $11.90. I would say the pullback is about done as well, as the stock has just given back around $1.80 from its recent highs.
Revenue possibilities for Zerenex are now over $1B/year after this news today on positive phase 2 results for the use in pre dialysis anemia, etc. I would think estimates from analysts before this news of $22-$24 will be raised a good bit.
With the news today for the potential for Zerenex to be additionally used for pre dialysis anemia, the potential reveune stream has tripled to quadrupled. However the stock only going up $2 makes little sense, as the earnings potential has gone up by multiples. I believe with FDA approval of Zerenex for both Primary Kidney Disease for those on Dialysis, as well as pre dialysis anemic patients, the stock price could go north of $50 IMO. Hard to believe the stock isn't worth $20-$25 right now for the huge potential.
EPS of $.07 for the qtr after adding back amortization($.02), and stock based compensation($.01). Sector is getting 20-25 PEs and higher, so seems if they continue to do as well(and CEO sure suggests they will), target could be north of $6.
Phase 2 trail blockbuster results substantiated the use for Zerenex in pre Kidney Dialysis as well as for patients on Kidney Dialysis. Use of Zerenex in pre kidney dialysis would possibly triple -quadruple overall revenues. That news changed everything, and that's why 100% of the analyst estimates have gone up to the md $20s since last week. Bottom line is, if Zerenex gets FDA approval for both Kidney Dialysis and pre kidney dialysis, the stock could be worth north of $50.